Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti–Aquaporin-4 Antibody–Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results From the Global NMO SPOTLIGHT Registry